Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

Abstract Number: 1083 • ACR Convergence 2021
Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes in Flares During the COVID-19 Pandemic: An International Survey
Samira Nazzar Romero¹, Lakshmi Moorthy², Jennifer Tousseau³, Sivia Lapidus⁴, Mariana Correia Marques⁵, Leanne Mansfield⁶, Marinka Twilt⁷, Grant Schulert⁸, Maria Gutierrez⁹, Saskya Angevare¹⁰, Fatma Dedeoglu¹¹ and Karen Durrant¹², ¹University of California Los Angeles, Los Angeles, CA, ²Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ³Autoinflamamtory Alliance, Lincoln, CA, ⁴The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Montclair, NJ, ⁵UPMC Children`s Hospital of Pittsburgh, Pittsburgh, PA, ⁶Hospital for Special Surgery, New York, NY, ⁷Alberta Children's Hospital, Calgary, AB, Canada, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹John's Hopkins, Baltimore, MD, ¹⁰Autoinflammatory Alliance / Kaisz / ENCA as patient organizations, Amersfoort, Netherlands, ¹¹Boston Children's Hospital, Boston, MA, ¹²Autoinflammatory Alliance, San Francisco, CA
Background/Purpose: The exaggerated inflammatory responses to the SARS-CoV-2 virus and the paucity of data on COVID-19 infection risk in systemic autoinflammatory disease (SAID) patients posed…
Abstract Number: 0417 • ACR Convergence 2020
Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes
Eduardo Martin-Nares¹, Janette Furuzawa-Carballeda¹, Ángel Alexis Priego-Ranero¹, Isela Chan-Campos¹, Gladys Sulikey Herrera-Noguera¹, Fidel López-Verdugo¹ and Gabriela Hernandez-Molina¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico
Background/Purpose: Patients with IgG4-related disease (IgG4-RD) can be classified in clinical phenotypes which differ in terms of demographics, clinical and serological features. Whether there are…
Abstract Number: 0645 • ACR Convergence 2020
Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis
Anne-Claire Desbois¹, Cindy Marques¹, Leila Lefèvre¹, Serge Barmo¹, Camille Lorenzo¹, Mathilde Leclercq¹, Gaëlle Leroux¹, Chloé Comarmond¹, Catherine Chapelon-Abric¹, Fanny Domont¹, David Saadoun¹ and Patrice Cacoub¹, ¹AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Paris, France
Background/Purpose: To investigate the prevalence, clinical features and outcomes of coronavirus disease 2019 (COVID-19) among sarcoidosis patients.Methods: We retrospectively collected clinical features, treatments and outcomes…
Abstract Number: 1033 • ACR Convergence 2020
Systemic Treatment in Sarcoidosis. Study of 377 Patients from a Single University Hospital
David Martinez-Lopez¹, Raul Fernandez-Ramon², José Luis Martín-Varillas³, Lara Sanchez-Bilbao², Inigo Gonzalez-Mazon⁴, Jorge Javier Gaitan-Valdizan⁵, Rosalia Demetrio-Pablo², Miguel Ángel González-Gay⁶ and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Sierrallana, Torrelavega, Spain, ⁴Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Sarcoidosis is a multisystemic disease characterized by the formation of non-necrotizing granulomas. The most frequently affected organs are the lungs, skin and eyes. Systemic…
Abstract Number: 1051 • ACR Convergence 2020
Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers
Kristin D'Silva¹, Iazsmin Bauer Ventura², Marcy Bolster³, Flavia Castelino⁴, Amita Sharma¹, Brent Little¹, Ayodeji Adegunsoye², Mary Strek², Sydney Montesi¹ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²University of Chicago, Chicago, IL, ³Massachusetts General Hospital, Concord, MA, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Many patients with interstitial lung disease (ILD) have autoimmune features without a distinct rheumatic disease and are thus designated as having interstitial pneumonia with…
Abstract Number: 1160 • ACR Convergence 2020
Treatment Intensity and Impact on Bone Lesion Evolution and Distribution Patterns in Severe Chronic Recurrent Multifocal Osteomyelitis
Aleksander Lenert¹, T. Shawn Sato², Sedat G Kandemirli¹, Patrick Ten Eyck¹ and Polly Ferguson³, ¹University of Iowa, Iowa City, IA, ²University of Iowa, Iowa City, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: To compare bone lesion evolution and bone lesion distribution patterns identified by whole body magnetic resonance imaging (WB-MRI) by treatment intensity in patients with…
Abstract Number: 1166 • ACR Convergence 2020
Use of Rituximab to Treat COPA Syndrome: A Multi-Institutional Cohort
Leigh Stubbs¹, Isabella Osuna², Tarin Bigley³, Michal Cidon⁴, Kristen Mengwasser⁵, Simon Helfgott⁶, Marietta DeGuzman⁷, Manuel Silva-Carmona⁸ and Tiphanie Vogel⁹, ¹Baylor College of Medicine, Houston, TX, ²Department of Pediatrics, Division of Rheumatology, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas, USA, Houston, TX, ³Washington University in St. Louis, Saint Louis, MO, ⁴CHLA, Los Angeles, CA, ⁵Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts, USA, Boston, MA, ⁶BWH- HMS, Boston, MA, ⁷Baylor College of Medicine, Houston, ⁸Department of Pediatrics, Division of Pulmonology Medicine, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas, USA, Houston, TX, ⁹Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Coatomer protein complex subunit α (COPA) syndrome is a rare genetic multisystem autoimmune disorder inherited in an autosomal dominant manner. Onset typically occurs in…
Abstract Number: 1443 • ACR Convergence 2020
High-dimensional Analyses of Checkpoint-inhibitor Related Arthritis Synovial Fluid Cells Reveal a Unique, Proliferating CD38hi Cytotoxic CD8 T Cell Population Induced by Type I IFN
Runci Wang¹, Karmela Kim Chan², Amy Cunningham-Bussel¹, Gregory Vitone³, Aidan Tirpack², Caroline Benson², Gregory Keras⁴, Anna Helena Jonsson⁵, Michael Brenner⁵, Laura Donlin⁶, Anne Bass⁷ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, ⁴Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, Weill Cornell Medicine, New York, ⁷Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Checkpoint inhibitors (CI) used to treat cancer frequently trigger immune-related adverse events, including inflammatory arthritis. CI-related arthritis (CIrA) occurs in ~5% of treated patients,…
Abstract Number: 1577 • ACR Convergence 2020
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis
Jeffrey Sarazin¹, Ann Impens², Nada Abdulaziz¹, Stacey Anderson³, Leslie Fecher¹, Christopher Lao¹ and Elena Schiopu¹, ¹Michigan Medicine, Ann Arbor, MI, ²Midwestern University, Ann Arbor, IL, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
Abstract Number: 1631 • ACR Convergence 2020
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
Mark Lebwohl¹, Darren West², Alan Mendelsohn³, Stephen Rozzo³ and Giampiero Girolomoni⁴, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Spectrum Dermatology, Scottsdale, AZ, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁴Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Tildrakizumab (TIL) is a high‐affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis. We evaluated adverse…
Abstract Number: 1637 • ACR Convergence 2020
Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan
Jun Shimizu¹, Yoshihisa Yamano¹, Kimito Kawahata² and Noboru Suzuki¹, ¹St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: We conducted a retrospective survey study in 2009 and collected clinical data of 239 patients with relapsing polychondritis (RP). Using the survey data, we…
Abstract Number: 0090 • ACR Convergence 2020
110 Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Rheumatology Disease Unit: Fracture, Neuropathy, and Pernicious Anemia Are Clues to Recognition
Michael Lovy¹ and Andrew Dulalia¹, ¹Desert Oasis Healthcare, Palm Springs, CA
Background/Purpose: Monoclonal gammopathy of undetermined significance (MGUS) has been associated with osteoporosis, neuropathy, pernicious anemia, and low vitamin B12, and may precede multiple myeloma and…
Abstract Number: 0093 • ACR Convergence 2020
Review of Gastrointestinal Manifestations of Kohlmeier-Degos Disease
Samantha Sattler¹, Lee Shapiro² and Cynthia Magro³, ¹Albany Medical College, Albany, NY, ²Albany Medical College, Stillwater, NY, ³Weill Cornell Medicine, New York, NY
Background/Purpose: Kohlmeier-Degos disease is a rare obliterative vasculopathy that can present in a benign cutaneous form or with potentially malignant systemic involvement. While the benign…
Abstract Number: 0100 • ACR Convergence 2020
Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases
Cristobal Pavez Perales¹, Ana Quiles Rocher², Elena Grau Garcia³, Marta De la Rubia Navarro¹, Samuel Leal Rodriguez⁴, Roxana Gonzalez Mazario¹, Jorge Juan Fragio Gil¹, Cristina Alcañiz Escandell³, Jose Ivorra Cortes¹, Inmaculada Chalmeta Verdejo¹, Luis Gonzalez Puig⁵, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Francisco Miguel Ortiz Sanjuan⁴, Elvira Vicens Bernabeu⁴, Carmen Najera Herranz¹, Ines Canovas Olmos¹ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Medical School, UCV, Valencia, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department, HUP La Fe, Valencia, Spain, ⁵Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain
Background/Purpose: Patients with rheumatic diseases (RD) are at higher risk of latent tuberculosis infection (LTBI) reactivation. To detect and treat it before starting treatment, especially with biological therapies, decrease the reactivation risk. Diagnosis is carried…
Abstract Number: 0414 • ACR Convergence 2020
Clinical Characteristics of an Internet-Based Cohort of Participants with a Self-Reported Diagnosis of Cryoglobulinemic Vasculitis or IgA Vasculitis
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Young⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹University of Kansas Medical Center, Overland Park, KS, ²David Geffen School of Medicine / University of California, Los Angeles, CA, ³Vasculitis Foundation, North Carolina, ⁴Vasculitis Foundation, Kansas City, ⁵University of South Florida, Tampa, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cyroglobulinemic vasculitis (CV) and IgA vasculitis are forms of small-vessel vasculitis characterized by immune complex deposition. The purpose of this study was to a)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].